BPC-157 + TB-500 Blend: Dosage, Benefits & Side Effects
By Peptide Assistant Editorial Team · · · 19 sources cited
Overview
The BPC-157 + TB-500 blend, commonly known as the 'Wolverine Stack,' combines the two most potent healing peptides available into a single vial for convenience. Synergy between the two is assumed, not shown: the one animal study of the combination (rat Achilles tendon repair, 2026) found no added benefit over either peptide alone, and no human study of the blend exists. BPC-157 drives angiogenesis, growth factor upregulation, and NO system stabilization while TB-500 (Thymosin Beta-4) promotes cell migration through actin regulation and provides potent systemic anti-inflammatory effects. Together they address the structural, vascular, inflammatory, and cellular components of tissue injury — making this the gold standard healing protocol in the peptide community.
Mechanism of Action
This blend pairs two peptides whose proposed healing mechanisms, described in cell and animal studies, are different: **BPC-157's contribution:** Upregulation of the VEGF receptor VEGFR2 and of growth hormone receptors (in rat and cell studies) drives new blood vessel formation (angiogenesis) at injury sites. Activation of the FAK-paxillin pathway promotes fibroblast and endothelial cell migration for wound closure. NO system stabilization maintains vascular tone and blood flow. Growth factor receptor amplification enhances the body's responsiveness to endogenous repair signals. **TB-500's contribution:** Thymosin Beta-4 sequesters G-actin monomers, regulating how actin filaments are assembled, which is essential for cell migration, the fundamental process by which repair cells reach injury sites. In cell and animal studies, full-length Thymosin Beta-4 blocks activation of NF-κB, the master inflammatory transcription factor, and lowers inflammatory mediators such as IL-1β. Full-length Thymosin Beta-4 also promoted hair follicle stem cell migration in rodents and cardiac repair in mice. These effects have not been shown for the TB-500 fragment, and the anti-inflammatory activity has been mapped to a part of the molecule that TB-500 does not contain. **Proposed interactions:** The rationale for combining them is that: (1) BPC-157 builds new blood vessels to supply the injury site while TB-500 enables repair cells to migrate there; (2) TB-500 controls inflammation while BPC-157 drives reconstruction; (3) BPC-157 provides local healing signals while TB-500 provides systemic anti-inflammatory coverage. This has not been borne out so far: in the only study that tested it (rat Achilles tendon repair), the combination did not heal better than either peptide alone.
BPC-157 + TB-500 Blend Benefits: What the Research Shows
- Both peptides have independent bodies of preclinical evidence — BPC-157 with 100+ animal and cell studies, and full-length Thymosin Beta-4 (rather than the TB-500 fragment) with decades of research including cardiac repair, wound healing, and neuroprotection in animals. Neither has controlled human evidence for injury healing.
- BPC-157 and TB-500 are proposed to act through different pathways: BPC-157 through angiogenesis and growth factor signaling, TB-500 through cell migration and actin dynamics. Whether this adds up to synergy is unproven; the authors of a 2026 rat tendon study that found no additive effect suggested the two may converge on shared downstream pathways.
- Full-length recombinant Thymosin Beta-4 (not TB-500) was tested in a randomized, placebo-controlled trial in 96 heart attack patients: infarct size at 90 days did not differ significantly overall, though it was smaller in the subgroup given the first dose within 8 hours of angioplasty (Cardiovascular Research, 2025).
- Anecdotal reports describe faster healing with the BPC-157/TB-500 combination than with either peptide alone, but no human trial has tested this, and the one controlled animal study (rat Achilles tendon, 2026) found no added benefit from combining them. The only published human use together is 4 patients in a retrospective knee-pain chart review.
- In theory, the combination could address all four phases of wound healing: hemostasis (vascular protection), inflammation, proliferation (angiogenesis + cell migration), and remodeling (growth factor-driven tissue maturation). This is a rationale, not a tested result.
BPC-157 + TB-500 Blend Dosage
- Standard blend vial: 5 mg BPC-157 / 5 mg TB-500 per vial (10 mg total). Reconstitute with 2 mL bacteriostatic water for 2.5 mg/mL of each peptide.
- Standard healing dose: 0.1–0.2 mL daily (250–500 mcg of each peptide), injected subcutaneously near the injury site. This is the most common protocol for musculoskeletal injuries.
- Loading phase (acute injuries): 500 mcg of each peptide daily for the first 2–4 weeks, then reduce to 250 mcg of each daily for maintenance.
- Systemic protocol (gut healing, general recovery): Inject into abdominal subcutaneous fat, 250–500 mcg of each daily.
- TB-500 front-loading variation: Some protocols use the blend daily for the first 2 weeks, then switch to every-other-day dosing, reflecting TB-500's longer biological activity.
- Typical cycle: 6–12 weeks for injury healing, depending on severity. Minor injuries (grade 1 sprains, mild tendinitis) may resolve in 4–6 weeks. Major injuries (partial tears, post-surgical) may require 8–12 weeks.
- Also available in 10 mg/10 mg vials for extended protocols or higher-dose needs.
Disclaimer: Dosing information is compiled from research literature and community protocols for educational purposes only. This is not medical advice. Always consult a qualified healthcare provider before starting any peptide protocol.
BPC-157 + TB-500 Blend Side Effects & Safety
Known Side Effects
- Injection site reactions — redness, mild swelling, or irritation, particularly during the first few days. More common with the blend due to higher total peptide concentration per injection.
- Mild headache — reported occasionally, usually during the first week of use.
- Temporary fatigue — some users report mild tiredness during the initial loading phase as the body diverts resources toward healing.
- Mild nausea — infrequent, typically associated with higher doses.
- Water retention — TB-500 can cause mild temporary water retention in some users. Usually resolves within the first 1–2 weeks.
- Theoretical VEGF/angiogenesis concern for those with active malignancies — same precaution as standalone BPC-157.
Safety Profile
The blend has not been safety-tested as a combination, and neither component has adequate human safety data. BPC-157 has no established lethal dose in animal studies, but its human record is three small uncontrolled studies. Full-length Thymosin Beta-4 has been through human clinical trials (intravenous in healthy volunteers, topical for wounds) with acceptable tolerability, but the TB-500 fragment used in this blend has no human exposure data according to the FDA. The FDA lists both BPC-157 and the TB-500 fragment among bulk drug substances that may present significant safety risks in compounding, and both are prohibited in sport by WADA. Contraindications are the same as for individual components: active malignancy (precaution due to angiogenic potential), pregnancy/breastfeeding, and known hypersensitivity. The blend does not suppress endogenous hormone production and requires no PCT. Individuals on anticoagulants should be aware that TB-500 may have mild effects on platelet function, though clinically significant interactions have not been reported. No drug interaction studies have been done for either peptide.
What to Expect
This timeline comes from user reports; the blend has not been studied in humans. Days 1–3: Users report that anti-inflammatory effects begin. Pain and swelling at the injury site may noticeably decrease. Users often say the combination gives faster symptom relief than either peptide alone, but no study has shown this. Week 1: Healing acceleration is apparent. Range of motion improves, pain decreases significantly. New blood vessel formation and cell migration are actively occurring at the tissue level. Weeks 2–4: This is the peak healing period. Users with acute injuries (sprains, strains, minor tears) often report 50–70% improvement. Chronic injuries that had plateaued begin progressing. Surgical recovery patients report faster-than-expected healing. Weeks 5–8: Tissue remodeling and maturation. The healed tissue gains strength and organization. Many acute injuries are fully resolved. Chronic tendinopathies show continued improvement. Weeks 9–12: Final remodeling phase. Tissue quality continues to improve. Most users taper dosing or discontinue as healing goals are met.
Common Stacks
GHK-Cu
GHK-Cu adds collagen remodeling and anti-inflammatory gene expression to the BPC-157/TB-500 angiogenesis and cell migration effects — creating a comprehensive three-peptide healing protocol.
Ipamorelin
Growth hormone amplifies tissue repair, and BPC-157's GH receptor upregulation means tissues are primed to respond. Adding Ipamorelin to the Wolverine Stack creates optimal conditions for recovery.
Storage & Handling
Store lyophilized powder refrigerated at 36–46°F (2–8°C). After reconstitution with bacteriostatic water, refrigerate and use within 4 weeks. Reconstitution: add 2 mL bacteriostatic water to a 5 mg/5 mg vial. Gently swirl to dissolve. Do not freeze reconstituted solution. Unreconstituted vials can be frozen at -4°F (-20°C) for long-term storage (12+ months).
Pricing & Available Variants
Prices sourced from peptides.gg marketplace. Prices may vary.
References
- Biçer O, Adanir O, Güleryüz Y, et al. Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: A histopathological and biomechanical study. Jt Dis Relat Surg. 2026.
- Tham A, Hodgkins CW, Kennedy JG. Investigational Peptides in Orthopaedic Practice: Evidence, Safety, and Patient Counseling for BPC-157, Thymosin Beta-4, and TB-500. J Am Acad Orthop Surg. 2026.
- Poolton JT, Minett J, Kazmi A. Human evidence for BPC-157 in orthopaedic and regenerative medicine: a systematic review of efficacy and safety. Acta Orthop Belg. 2026.
- Lee E, Padgett B. Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain. Altern Ther Health Med. 2021.
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. U.S. Food and Drug Administration. 2026.
- The Prohibited List. World Anti-Doping Agency. 2026.
- Vasireddi N, Hahamyan H, Salata MJ, et al. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS J. 2025.
- Hsieh MJ, Liu HT, Wang CN, et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. J Mol Med (Berl). 2017.
- Chang CH, Tsai WC, Lin MS, et al. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. J Appl Physiol (1985). 2011.
- Chang CH, Tsai WC, Hsu YH, et al. Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts. Molecules. 2014.
- Sikiric P, Seiwerth S, Rucman R, et al. Toxicity by NSAIDs. Counteraction by stable gastric pentadecapeptide BPC 157. Curr Pharm Des. 2013.
- Sosne G, Qiu P, Goldstein AL, et al. Biological activities of thymosin beta4 defined by active sites in short peptide sequences. FASEB J. 2010.
- Sosne G, Qiu P, Christopherson PL, et al. Thymosin beta 4 suppression of corneal NFkappaB: a potential anti-inflammatory pathway. Exp Eye Res. 2007.
- Sosne G, Szliter EA, Barrett R, et al. Thymosin beta 4 promotes corneal wound healing and decreases inflammation in vivo following alkali injury. Exp Eye Res. 2002.
- Philp D, Nguyen M, Scheremeta B, et al. Thymosin beta4 increases hair growth by activation of hair follicle stem cells. FASEB J. 2004.
- Bock-Marquette I, Saxena A, White MD, et al. Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair. Nature. 2004.
- Zhang Y, Dong Q, Bian X, et al. Recombinant human thymosin beta 4 improves ischemic cardiac dysfunction in mice and patients with acute ST-segment elevation myocardial infarction after reperfusion. Cardiovasc Res. 2025.
- Ruff D, Crockford D, Girardi G, et al. A randomized, placebo-controlled, single and multiple dose study of intravenous thymosin beta4 in healthy volunteers. Ann N Y Acad Sci. 2010.
- Guarnera G, DeRosa A, Camerini R. The effect of thymosin treatment of venous ulcers. Ann N Y Acad Sci. 2010.
Related Peptides
Track BPC-157 + TB-500 Blend in Your Protocol
Log your BPC-157 + TB-500 Blend doses, track consistency, and monitor your protocol with Peptide Assistant — completely free.
Start Tracking Free